Clinical trial / 2016
Curcumin supplementation prevented a 6-month cognitive decline seen with placebo, but showed no other differences across cognitive tests in older adults.
A 12-month randomized, placebo-controlled, double-blind study evaluated the effect of 1500 mg/d BiocurcumaxTM versus placebo in 96 community-dwelling older adults. A significant time×treatment interaction was detected for the Montreal Cognitive Assessment (F=3.85, P<0.05), driven by a decline in function in the placebo group at 6 months that was not seen in the curcumin group. No differences between the groups were observed for all other clinical and cognitive measures.
- Study type
- 12-month randomized, placebo-controlled, double-blind trial
- Who was studied
- 96 community-dwelling older adults
- What was measured
- Cognitive and clinical measures assessed at baseline, 6 months, and 12 months
THE PAPER
Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults.
Rainey-Smith SR, Brown BM, Sohrabi HR, Shah T, Goozee KG, Gupta VB, Martins RN. Br J Nutr, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.